TD Cowen analyst Tyler Van Buren raised the firm’s price target on Gilead (GILD) to $115 from $110 and keeps a Buy rating on the shares. The firm said they posred good Q3 results as sales and earnings beat. The company raised its HIV guidance andits Yeztugo launch looks encouraging.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $98 from $96 at RBC Capital
- Gilead price target raised to $128 from $125 at Oppenheimer
- Gilead price target raised to $130 from $120 at BMO Capital
- Gilead price target raised to $143 from $135 at Morgan Stanley
- Assembly Biosciences reports interim results from phase 1b study of ABI-5366